|
Immunological evaluation of influenza vaccine effectiveness against A/H1N1/pdm09 strains circulating in Iran
|
Atefeh Mohebbi1   , Abbas Jamali  2, Fatemeh Fotouhi3 , Ramin Yaghobi4 |
1- 1.Department of Microbiology, Fars Science and Research branch, Islamic Azad University, Fars, Iran . Department of Microbiology, College of Science Agriculture and Modern Technology, Shiraz Branch, Islamic Azad University, Shiraz, Iran
2- Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran , jamali@pasteur.ac.ir
3- Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
4- Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran |
|
|
Abstract: (537 Views) |
Background: In 2015-2016 flu season, the subtype A/H1N1/pdm09 was reported with a widespread of 92% in Iran. A phylogenetic study based on the HA protein located the viruses in the new subgroup 6B.1. Therefore, by observing this change, the effectiveness of the vaccine was investigated from an immunological point of view.
Materials and methods: The investigated viruses were selected from among the sequenced samples based on the diversity and abundance of substitutions, by aligning with the Bioedit software and drawing a phylogenetic tree by the maximum likelihood method in the Mega software, and were propagated by MDCK cells. Next, by injecting two doses of human influenza vaccine two weeks apart into the two rabbits, their serum on day (0) before immunization, 21 and 30 days after the injection, isolated and after treatment, the antibody produced was used for Hemagglutination inhibition (HI) test. The data were analyzed in the Excel chart.
Results: The mean HI titer in the positive control sample was 960, and in samples 831, 836, 807 and 808 were 40, 20, 180 and 120, respectively. The results showed that the antibody obtained from the vaccine had neutralizing properties against the circulating viruses, but it was significantly reduced compared to the reference strain (P<0.001). No titer was observed in the negative control sample.
Conclusion: The requirement of genetic and immunological evaluation of vaccine efficiency for influenza viruses is necessary every year; so it is essential to provide appropriate methods available to laboratories.
|
|
| Keywords: Influenza virus A/H1N1/pdm09, Hemagglutinin protein, HI test. |
|
|
Full-Text [PDF 769 kb]
(247 Downloads)
|
Semi-pilot: Basic |
Subject:
Virology
Received: 2023/04/22 | Accepted: 2023/08/12 | Published: 2024/02/29
|
|
|
|
|
|
|
| References |
1. Sedova ES, Shcherbinin DN, Migunov AI, Smirnov IA, Logunov DB, Shmarov MM, et al. Recombinant Influenza Vaccines. Acta Naturae 2012;4:17-27. [ DOI:10.32607/20758251-2012-4-4-17-27] 2. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010;28:4895-902. [ DOI:10.1016/j.vaccine.2010.05.031] 3. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011;162:19-30. [ DOI:10.1016/j.virusres.2011.09.022] 4. Caspard H, Mallory RM, Yu J, Ambrose CS. Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015-2016: A Systematic Review and Meta-Analysis. Open Forum Infect Dis 2017;4:ofx111. [ DOI:10.1093/ofid/ofx111] 5. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season [Internet]. Geneva: WHO. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season. 6. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines 2017;16:1-14. [ DOI:10.1080/14760584.2017.1334554] 7. Staneková Z, Varečková E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010;7:351. [ DOI:10.1186/1743-422X-7-351] 8. Sriwilaijaroen N, Suzuki Y. Molecular basis of the structure and function of H1 hemagglutinin of influenza virus. Proc Jpn Acad Ser B Phys Biol Sci 2012;88:226-49. [ DOI:10.2183/pjab.88.226] 9. Mallajosyula VVA, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A 2014;111:E2514-23. [ DOI:10.1073/pnas.1402766111] 10. Lee AJ, Das SR, Wang W, Fitzgerald T, Pickett BE, Aevermann BD, et al. Diversifying Selection Analysis Predicts Antigenic Evolution of 2009 Pandemic H1N1 Influenza A Virus in Humans. J Virol. 2015 ;89:5427-40. [ DOI:10.1128/JVI.03636-14] 11. Mohebbi A, Fotouhi F, Jamali A, Yaghobi R, Farahmand B, Mohebbi R. Molecular epidemiology of the hemagglutinin gene of prevalent influenza virus A/H1N1/pdm09 among patient in Iran. Virus Res. 2019;259:38-45. [ DOI:10.1016/j.virusres.2018.10.001] 12. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season [Internet]. Geneva: WHO. 2015. Available from: https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2015-2016/201502_recommendation.pdf?sfvrsn=6d83789f_15&download=true 13. Moasser E, Behzadian F, Moattari A, Fotouhi F, Rahimi A, Zaraket H, et al. Molecular characterization and phylogenetic analysis of human influenza A viruses isolated in Iran during the 2014-2015 season. Arch Virol 2017;162:1975-84. [ DOI:10.1007/s00705-017-3323-3] 14. Arunorat J, Charoenvisal N, Woonwong Y, Kedkovid R, Thanawongnuwech R. Determination of current reference viruses for serological study of swine influenza viruses after the introduction of pandemic 2009 H1N1 (pdmH1N1) in Thailand. J Virol Methods 2016;236:5-9. [ DOI:10.1016/j.jviromet.2016.06.010] 15. Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel) 2014;2:707-34. [ DOI:10.3390/vaccines2040707] 16. Strengell M, Ikonen N, Ziegler T, Julkunen I. Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties. PLoS One 2011;6:e25848. [ DOI:10.1371/journal.pone.0025848] 17. Zacour M, Ward BJ, Brewer A, Tang P, Boivin G, Li Y, et al; Public Health Agency of Canada and Canadian Institutes of Health Influenza Research Network (PCIRN). Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. Clin Vaccine Immunol 2016;23:236-42. [ DOI:10.1128/CVI.00613-15] 18. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325:197-201. [ DOI:10.1126/science.1176225] 19. Yavarian J, Naseri M, Shadab A, Shafiei Jandaghi NZ, Mokhtari Azad T. Epidemiological aspects of pandemic influenza A(H1N1) virus from 2009 to 2011 in Iran. Influenza and other Respiratory Viruses 2012;6:e74-6. [ DOI:10.1111/j.1750-2659.2012.00357.x] 20. Center for Diseases Control and Prevention. Summary of the 2011-2012 Influenza Season [Internet]. USA: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD); 2012. Available from: https://www.cdc.gov/flu/pastseasons/1112season.htm#print. 21. Tavakoli F, Moattari A, Shamsi Shahr Abadi M, Kadivar MR, Khodadad N, Pirbonyeh N, et al. Antigenic Variation of the Haemagglutinin Gene of the Influenza A (H1N1) pdm09 Virus Circulating in Shiraz, February-April 2013. Iran J Immunol 2015;12:198-208. 22. Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, et al. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis 2016 ;213:1546-56. [ DOI:10.1093/infdis/jiv577] 23. Korsun N, Angelova S, Gregory V, Daniels R, Georgieva I, McCauley J. Antigenic and genetic characterization of influenza viruses circulating in Bulgaria during the 2015/2016 season. Infect Genet Evol 2017 ;49:241-250. [ DOI:10.1016/j.meegid.2017.01.027] 24. Summary of the influenza 2015-2016 season in Europe [Internet]. European :union:: European Centre for Disease Prevention and Control; 2016. Available from: https://www.ecdc.europa.eu/en/publications-data/summary-influenza-2015-2016-season-europe. 25. Castelán-Vega JA, Magaña-Hernández A, Jiménez-Alberto A, Ribas-Aparicio RM. The hemagglutinin of the influenza A(H1N1)pdm09 is mutating towards stability. Adv Appl Bioinform Chem 2014;7:37-44. [ DOI:10.2147/AABC.S68934] 26. Wedde M, Biere B, Wolff T, Schweiger B. Evolution of the hemagglutinin expressed by human influenza A(H1N1)pdm09 and A(H3N2) viruses circulating between 2008-2009 and 2013-2014 in Germany. Int J Med Microbiol 2015;305:762-75. [ DOI:10.1016/j.ijmm.2015.08.030] 27. Mukherjee A, Nayak MK, Dutta S, Panda S, Satpathi BR, Chawla-Sarkar M. Genetic Characterization of Circulating 2015 A(H1N1)pdm09 Influenza Viruses from Eastern India. PLOS One 2016;11:e0168464. [ DOI:10.1371/journal.pone.0168464] 28. Sun S, Wang Q, Zhao F, Chen W, Li Z. Prediction of Biological Functions on Glycosylation Site Migrations in Human Influenza H1N1 Viruses. PLOS One 2012;7:e32119. [ DOI:10.1371/journal.pone.0032119] 29. Kim P, Jang YH, Kwon SB, Lee CM, Han G, Seong BL. Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs. Viruses 2018;10:183. [ DOI:10.3390/v10040183] 30. Tate MD, Job ER, Deng Y-M, Gunalan V, Maurer-Stroh S, Reading PC. Playing Hide and Seek: How Glycosylation of the Influenza Virus Hemagglutinin Can Modulate the Immune Response to Infection. Viruses 2014;6:1294-316. [ DOI:10.3390/v6031294] 31. Kosik I, Ince WL, Gentles LE, Oler AJ, Kosikova M, Angel M, et al. Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs. PLoS Pathog 2018;14:e1006796. [ DOI:10.1371/journal.ppat.1006796] 32. She YM, Farnsworth A, Li X, Cyr TD. Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines. Sci Rep 2017;7:10232. [ DOI:10.1038/s41598-017-10714-2] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Mohebbi A, Jamali A, Fotouhi F, Yaghobi R. Immunological evaluation of influenza vaccine effectiveness against A/H1N1/pdm09 strains circulating in Iran. MEDICAL SCIENCES 2024; 34 (1) :1-11 URL: http://tmuj.iautmu.ac.ir/article-1-2121-en.html
|
